India just put 9 out of every 10 "high-risk" drug factories it inspected on notice — stop-production orders, licence suspensions, some outright shut down.
The reason isn't subtle.
It's dead children.
In 2022, an Indian-made cough syrup was linked to child deaths abroad.
70 kids in Gambia.
More in Uzbekistan.
12 in Cameroon.
The culprit: diethylene glycol — an industrial solvent — found where it should never be, in medicine meant for toddlers.
The world's "pharmacy" had a quality problem nobody could ignore anymore.
Since late 2022, regulators ran more than 960 risk-based inspections across the country's drug facilities.
The results, revealed by Drugs Controller General Rajeev Raghuvanshi at the Global Drug Regulatory Conclave in Delhi:
That's roughly a 90% strike rate on every high-risk site they walked into.
Not a random audit. A targeted purge.
Here's where it gets interesting for a regulator overseeing 10,000+ factories and nearly 1 million pharmacies with limited manpower.
CDSCO has digitised over 99% of its processes.
And it's piloting AI tools to:
In other words — the same intelligence wave reshaping software is now deciding which drug factory gets raided next.
India supplies roughly 20% of the world's generic medicines.
When quality slips here, it doesn't stay local — it kills children thousands of miles away.
This crackdown is India trying to prove the "pharmacy of the world" tag still deserves trust.
The real test isn't the 90% enforcement number.
It's whether the next cough syrup bottle is safe before anyone has to count the bodies.
That's all for now!
